Showing 11-20 of 531 results for "".
ELEVATE (Qulipta for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments; NCT04740827)
https://practicalneurology.com/programs/practical-neurology/elevate-qulipta-for-prophylaxis-of-migraine-in-participants-who-failed-previous-oral-prophylactic-treatments-nct04740827/31255/Patricia Pozo-Rosich, MD, PhD, Headache Specialist from the Vall d’Hebron University Hospital in Barcelona, Spain, provides an overview of the ELEVATE clinical trial.Seeking Breakthroughs: The Physician Perspective
https://practicalneurology.com/columns/practice-management/the-physician-perspective/30193/A roundtable discussion with Claudia A. Chiriboga, MD, MPH; Jeffrey L. Cummings, MD, ScD; and Nir Lipsman, MD, PhDMedication-Overuse Headache
https://practicalneurology.com/diseases-diagnoses/headache-pain/medication-overuse-headache/30281/Questions and answers from Nina Tsakadze, MD, PhD; Natasha Antonovich; PharmD; and Fabian Rossi, MD- Dementia and Driving: When Should You Put on the Brakes?https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0606DrivingFea-pdf/31302/In the June 2006 issue of *Practical Neurology*, Heather Tuckman, PsyD, John Gordon, PhD, Steven Mandel, MD, and Edward Maitz, PhD explore the critical intersection between dementia and driving safety, illustrated through the case of Harold. Harold exhibited troubling behaviors, such as hiding keys
How Timing, Titration Speed, and Antiseizure Medication Burden Influence VNS Therapy Outcomes in Epilepsy
https://practicalneurology.com/programs/practical-neurology/how-timing-titration-speed-and-antiseizure-medication-burden-influence-vns-therapy-outcomes-in-epilepsy/39917/Ryan Verner, PhD, discusses findings from the large, global CORE-VNS study, including how earlier vagus nerve stimulation use and lower baseline antiseizure medication burden were associated with improved clinical response.Factors Influencing the Selection of CSF Tests for Alzheimer Disease
https://practicalneurology.com/videos/neurology-in-motion/factors-influencing-the-selection-of-csf-tests-for-alzheimer-disease/35726/Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses key factors influencing the selection of cerebrospinal fluid tests for Alzheimer disease.How MR Fingerprinting Is Transforming Epilepsy Imaging, Surgical Evaluation, and Outcome Prediction
https://practicalneurology.com/programs/practical-neurology/how-mr-fingerprinting-is-transforming-epilepsy-imaging-surgical-evaluation-and-outcome-prediction/39909/Irene Wang, PhD, Cleveland Clinic, Cleveland, OH, describes how MR fingerprinting, a novel quantitative MRI technique, improves lesion detection, tissue characterization, and presurgical evaluation in patients with drug-resistant epilepsy.Factors Influencing the Selection of Amyloid PET Tests for Alzheimer Disease
https://practicalneurology.com/videos/neurology-in-motion/factors-influencing-the-selection-of-amyloid-pet-tests-for-alzheimer-disease/37135/Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses key factors influencing the selection of amyloid PET tests for Alzheimer disease.INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)
https://practicalneurology.com/diseases-diagnoses/movement-disorders/intrepid-subthalamic-nucleus-deep-brain-stimulation-parkinson-disease/48741/Jerrold L. Vitek, MD, PhD, Head of the Neurology Department at the University of Minnesota, Minneapolis, MN, provides an overview of the INTREPID clinical trial which assessed subthalamic nucleus deep brain stimulation in patients with Parkinson disease.How to Communicate the Results of Alzheimer Disease Biomarker Tests with Patients
https://practicalneurology.com/videos/neurology-in-motion/how-to-communicate-the-results-of-alzheimer-disease-biomarker-tests-with-patients/39733/Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses how to communicate the results of Alzheimer disease biomarker tests with patients.